Exhibit 99.1

                                                     COMPANY CONTACT:

                                                     Rhonda F. Rhyne
                                                     rrhyne@cardiodynamics.com
                                                     800-778-4825, Ext. 1013



      CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical
             Parameters and Electronic Medical Record Compatibility


SAN DIEGO, CA--September 28, 2007--CardioDynamics (Nasdaq: CDIC), the innovator
and leader of BioZ(R) Impedance Cardiography (ICG) technology, today announced
the Company has received market clearance from the U.S. Food and Drug
Administration (FDA) for new ICG clinical parameters and electronic medical
record (EMR) interface capability for its BioZ Dx System. The BioZ Dx is the
product of a co-development partnership between the Company and Philips Medical
Systems that leverages each company's technology and expertise.

The new ICG clinical parameters include total arterial compliance (TAC) and Q-C
time interval (QC). TAC allows the assessment of peripheral artery elasticity,
an early marker of peripheral artery and cardiovascular disease. Monitoring TAC
may allow earlier identification of cardiovascular risk not apparent with
standard tools, including blood pressure assessment, and earlier therapeutic
intervention which has been proven to delay or prevent cardiovascular disease
progression. QC has been demonstrated to offer enhanced assessment of cardiac
contractility. The Company's early clinical investigations have shown enhanced
association with more costly, but advanced cardiac diagnostic evaluation,
including ejection fraction. The Company believes that these parameters may
contribute to earlier and more cost-effective evaluation of heart failure, the
most costly disease for Medicare.



The Company also announced FDA 510(k) clearance for expanded BioZ Dx EMR
interface capability. By improving medical practice efficiency and patient
safety, EMR is viewed as a valuable component of the healthcare system. EMR has
been at the center of legislative discussions, with Congress and the Department
of Health and Human Services working to link Medicare reimbursement to EMR
processing. This has resulted in an increasing demand by physician offices for
EMR capability. The BioZ Dx EMR interface is designed to operate in conjunction
with the Company's proprietary PC software, BioZportTM, which automatically
sends BioZ ICG clinical data to the customer's local PC network in one of three
industry-accepted formats. The data can then be easily integrated into each
patient's electronic medical record.

Michael K. Perry, CardioDynamics' Chief Executive Officer, stated, "We are very
pleased to receive FDA 510(k) clearance for these BioZ Dx enhancements. As the
innovator of ICG technology, we are committed to ongoing product development and
clinical research to prove the increasing clinical value of ICG and to provide
clinicians and patients with the most advanced heart monitoring technology
available."

Perry added, "The BioZ Dx EMR capability will assist in improving overall
efficiency in cardiac care and physician office environments by providing
clinicians with access to vital ICG data, when and where they need it."



About CardioDynamics:
CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG). The Company
develops, manufactures and markets noninvasive diagnostic and monitoring
technologies and electrodes. The Company's ICG Systems are being used by
physicians around the world to help battle the number one killer of men and
women--cardiovascular disease. Partners include GE Healthcare and Philips
Medical Systems. For additional information, please refer to the company's Web
site at www.cdic.com.


Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, such as future product
introductions, market size, potential, growth and penetration rates, the
accuracy of which is necessarily subject to uncertainties and risks including
the Company's primary dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as other risks
detailed in the Company's filings with the SEC, including its 2006 Form 10-K.
The Company does not undertake to update the disclosures contained in this press
release.